Role of intravenous cloxacillin for inpatient infections

Medecine et Maladies Infectieuses

Volumn 42, Issue 6, 2012, Pages 241-246

  Bru, J P ^a   Garraffo, R ^b  

^a Service réanimation Centre Hospitalier Région d'Annecy   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

Cloxacillin; MSSA; PK PD relationship

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM DERIVATIVE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; GLYCOPEPTIDE; ISOPENICILLIN N; LINEZOLID; METICILLIN; OXACILLIN; PANTON VALENTINE LEUKOCIDIN; PENICILLIN G; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTINE DALFOPRISTINE; RIFAMPICIN; TEICOPLANIN; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

AGING; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL ENDOCARDITIS; CATHETER INFECTION; CLOSTRIDIUM DIFFICILE; COMMUNICABLE DISEASE; CONTINUOUS INFUSION; COST OF ILLNESS; DEVICE INFECTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECOLOGY; FRANCE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTIOUS ARTHRITIS; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PHARMACODYNAMICS; PREVALENCE; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOXACILLIN; HUMANS; INJECTIONS, INTRAVENOUS; INPATIENTS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84862989692     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.10.015     Document Type: Review

References (36)

1. European Society of Cardiology (ESC). Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). The task force on the prevention, diagnosis and treatment of infective endocarditis of the ESC. European Heart Journal.
2. Hoen B, Celard M, Alla F, LeMoing V, Doco-Lecompte T, Tattevin P, et al. Continuing changing profile of infective endocarditis. Results of a repeat one-year population based survey in France (IE2008). In: 50e ICAAC; Boston 2010; K-2166.
3. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-12.
4. Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997, 27:29-33.
5. Frimodt-Moller N. How predictive is PK/PD for antibacterial agents?. Int J Antimicrob Agents 2002, 19:333-339.
6. Mentions légales orbénine gélules, IV (ML amalgamées Orbénine® 2011-2/Mai 2011). http://www.afssaps.fr/content/search%3FSearchText=oxacilline%26ok=Valider.
7. Bergan T., Oydvin B. Cross-over study of penicillin pharmacokinetics after intravenous infusions. Chemotherapy 1974, 20:263-279.
8. Mattie H., De Marie S., Slaghuis G., Rozing P.M., Van Strijen E. Diffusion of cloxacillin into synovial tissue. Br J Clin Pharmac 1992, 34:275-277.
9. Odenholt I. Prediction of individual antibiotic dose in the clinic. http://www.worldpharma2010.org/pp/W29.2.pdf.
10. Société de pathologie infectieuse de langue française (SPILF). Recommandations de pratique clinique. Infections ostéo-articulaires sur matériel (prothèse, implant, ostéosynthèse). Texte court. Version 6 définitive du 13 mai 2009.
11. Reverdy M.E., Coignard S., Dubreuil L., Bouvet A., Fleurette J. Activité in vitro de la cloxacilline sur les staphylocoques, les streptocoques du groupe A et Clostridium perfringens. Index inhibiteurs sériques. Med Mal Infect 1994, 24:898-905.
12. Reverdy M.E., Fleurette J., Nervi C., Etienne J. Bactéricidie comparée de la cloxacilline seule et en association sur S. aureus. Med Mal Infect 1996, 26:504-509.
13. Pilly E. Maladies infectieuses et tropicales. Ouvrage du collège des universitaires de maladies infectieuses et tropicales (CMIT), 2010, 22e édition-septembre 2009.
14. INVS. Résistance aux anti-infectieux. Rappel de la problématique. 23 octobre 2006 (mise à jour 9 juin 2010) http://www.invs.sante.fr/surveillance/resistance/problematique.htm.
15. EMEA. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the develpment of new antibacterial agents. Technical report, 2009, http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx%3FID=444.
16. Tacconelli E., De Angelis G., Cataldo M.A., Pozzi E., Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant S. aureus (MRSA) isolation?. A systematic review and meta-analysis. J Antimicrob chemother 2008, 61(1):26-38.
17. Anonymous Recent trends in antimicrobial resistance among streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience EUROSURVEILLANCE, 2008; 13(40):51, 533-8, http://www.eurosurveillance.org/.
18. ONERBA. Résistance aux antibiotiques en France. Résultats 1998-2009 des réseaux fédérés dans l'ONERBA. Poster N-01. http://www.onerba.org/download/JNI2010_poster_ONERBA.pdf.
19. Lorette G., Beaulieu P., Allaert F.A., Mahmoudi A., Jarlier V. Superficial community-acquired skin infections: prevalence of bacteria and antibiotic susceptibility in France. J Eur Acad Dermatol Venereol 2009, 23(12):1423-1426.
20. Bernard P., Jarlier V., Santerre-Henriksen A. Antibiotic susceptibility of S. aureus strains responsible for community-acquired skin infections. Ann Dermatol Venereol 2008, 135(1):13-19.
21. Thibaut S., Caillon J., Huart C., Grandjean G., Lombrail P., Potel G., et al. Susceptibility to the main antibiotics of Escherichia coli and Staphylococcus aureus strains identified in community acquired infections in France (MedQual, 2004-2007). Med Mal Infect 2010, 40(2):74-80.
22. Köck R., Becker K., Cookson B., van Gemert-Pijnen J.E., Harbarth S., Kluytmans J., et al. Methicillin-resistant S. aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010, 15(42):pii19688.
23. Cooke F.J., Brown N.M. Community-associated methicillin-resistant Staphylococcus aureus infections. Br Med Bull 2010, 94:215-227.
24. Thibaut S., Caillon J., Lepelletier D., Lombrail P., Potel G., Ballereau F., et al. Who are the carriers of MRSA in the community? A prospective study in the Pays de la Loire region of France. Clin Microbiol Infect 2010, 16:915-920.
25. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Infect 1998, 40(1):1-15.
26. Fortún J., Navas E., Martínez-Beltrán J., Pérez-Molina J., Martín-Dávila P., Guerrero A., et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001, 33(1):120-125.
27. Chambers H.F., Miller R.T., Newman M.D. Right-sided S. aureus endocarditis in intravenous drug abusers: two-weeks combination therapy. Ann Intern Med 1988, 109(8):619-624.
28. Chang F.Y. Staphylococcus aureus bacteremia endocarditis. J Immunol Microbiol Infect 2000, 33:63-68.
29. Stevens D.L., Smith L.G., Bruss J.B., McConnell-Martin M.A., Duvall S.E., Todd W.M., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000, 44(12):3408-3413.
30. Nichols R.L., Graham D.R., Barriere S.L., Rodgers A., Wilson S.E., Zervos M., et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999, 44(2):263-273.
31. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355(7):653-665.
32. Rijinders M.I., Deurenberg R.H., Boumans M.L., Hoogkamp-Korstanje J.A., Beisser P.S., Stobbering E.E. Flucloxacillin, still the empirical choice for putative S. aureus infections in intensive care units in the Netherlands. J Antimicrob Chemother 2009, 64(5):1029-1034.
33. Jensen A.G., Wachmann C.H., Espersen F., Scheibel J., Skinhoj P., Frimodt-Moller N. Treatment and outcome of S. aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002, 162(1):25-32.
34. Hughes D.W., Frei C.R., Maxwell P.R., Green K., Patterson J.E., Crawford G.E., Lewis J.S. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible S. aureus. Antimicrob Agents Chemother 2009, 53(5):2014-2019.
35. Ribera E., Gomez-Jimenez J., Cortes E., del Valle O., Planes A., Gonzales-Alujas T., et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided S. aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996, 125(12):969-974.
36. Plan antibiotiques 2007-2010: propositions du Comité de suivi pour la deuxième phase du Plan pour préserver l'efficacité des antibiotiques (27/11/2007). JMA/DGS/R13/septembre 2007.